Essential thrombocythemia - Pipeline Insight, 2021
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Essential thrombocythemia – Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Essential thrombocythemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Essential thrombocythemia: Overview
Essential thrombocythemia, also known as ET, is a rare disease. Essential thrombocytosis (primary thrombocythemia) is a nonreactive, chronic myeloproliferative disorder in which sustained megakaryocyte proliferation leads to an increase in the number of circulating platelets. Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding. Less common consequences in the later stages of ET include a transformation to myelofibrosis (marrow scarring) or acute leukemia. The causes of ET are still unknown. About half of ET patients have a mutation called JAK2V617F within their blood-forming cells, which leads to many characteristic features of the disease. ET is often detected on blood tests done for other reasons, before there are any symptoms. Additional tests may include: Complete blood count, blood smear, genetic testing, and bone marrow test. Treatments for ET can vary depending on a patient's symptoms. Some patients may not need active treatment but should still be monitored by a physician expert. Treatment includes: Low-dose aspirin, Platelet-lowering medications, and Plateletpheresis.
'Essential thrombocythemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Essential thrombocythemia pipeline landscape is provided which includes the disease overview and Essential thrombocythemia treatment guidelines. The assessment part of the report embraces, in depth Essential thrombocythemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Essential thrombocythemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Essential thrombocythemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Essential thrombocythemia Emerging Drugs
The Phase III multi-site, open-label, randomized, active-controlled study will compare the efficacy, safety, and tolerability and pharmacokinetics of P1101 as second line therapy for ET as compared with anagrelide, a commonly used oral platelet-reduction therapy.
Further product details are provided in the report……..
Essential thrombocythemia: Therapeutic Assessment
This segment of the report provides insights about the different Essential thrombocythemia drugs segregated based on following parameters that define the scope of the report, such as:
Essential thrombocythemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Essential thrombocythemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Essential thrombocythemia drugs.
Essential thrombocythemia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Essential thrombocythemia – Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Essential thrombocythemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Essential thrombocythemia: Overview
Essential thrombocythemia, also known as ET, is a rare disease. Essential thrombocytosis (primary thrombocythemia) is a nonreactive, chronic myeloproliferative disorder in which sustained megakaryocyte proliferation leads to an increase in the number of circulating platelets. Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding. Less common consequences in the later stages of ET include a transformation to myelofibrosis (marrow scarring) or acute leukemia. The causes of ET are still unknown. About half of ET patients have a mutation called JAK2V617F within their blood-forming cells, which leads to many characteristic features of the disease. ET is often detected on blood tests done for other reasons, before there are any symptoms. Additional tests may include: Complete blood count, blood smear, genetic testing, and bone marrow test. Treatments for ET can vary depending on a patient's symptoms. Some patients may not need active treatment but should still be monitored by a physician expert. Treatment includes: Low-dose aspirin, Platelet-lowering medications, and Plateletpheresis.
'Essential thrombocythemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Essential thrombocythemia pipeline landscape is provided which includes the disease overview and Essential thrombocythemia treatment guidelines. The assessment part of the report embraces, in depth Essential thrombocythemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Essential thrombocythemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Essential thrombocythemia R&D. The therapies under development are focused on novel approaches to treat/improve Essential thrombocythemia.
This segment of the Essential thrombocythemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Essential thrombocythemia Emerging Drugs
- Ropeginterferon alfa-2b: PharmaEssentia
The Phase III multi-site, open-label, randomized, active-controlled study will compare the efficacy, safety, and tolerability and pharmacokinetics of P1101 as second line therapy for ET as compared with anagrelide, a commonly used oral platelet-reduction therapy.
- IMG-7289: Imago Biosciences
Further product details are provided in the report……..
Essential thrombocythemia: Therapeutic Assessment
This segment of the report provides insights about the different Essential thrombocythemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Essential thrombocythemia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Essential thrombocythemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Essential thrombocythemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Essential thrombocythemia drugs.
Essential thrombocythemia Report Insights
- Essential thrombocythemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Essential thrombocythemia drugs?
- How many Essential thrombocythemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Essential thrombocythemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Essential thrombocythemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Essential thrombocythemia and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Essential thrombocythemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Ropeginterferon alfa-2b: PharmaEssentia
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IMG-7289: Imago Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Essential thrombocythemia Key Companies
Essential thrombocythemia Key Products
Essential thrombocythemia- Unmet Needs
Essential thrombocythemia- Market Drivers and Barriers
Essential thrombocythemia- Future Perspectives and Conclusion
Essential thrombocythemia Analyst Views
Essential thrombocythemia Key Companies
Appendix
Executive Summary
Essential thrombocythemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Ropeginterferon alfa-2b: PharmaEssentia
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IMG-7289: Imago Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Essential thrombocythemia Key Companies
Essential thrombocythemia Key Products
Essential thrombocythemia- Unmet Needs
Essential thrombocythemia- Market Drivers and Barriers
Essential thrombocythemia- Future Perspectives and Conclusion
Essential thrombocythemia Analyst Views
Essential thrombocythemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Essential thrombocythemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Essential thrombocythemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Essential thrombocythemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Essential thrombocythemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
